MET and lung carcinoma: Similarly, loss of MET amplification has been reported in some lung cancer patients who received first- or third-generation EGFR-TKI and crizotinib at progression.18 We hypothesize that loss of MET amplification may contribute to the occurrence of drug resistance and disease recurrence.